Bruce W. Tomlinson
Nessuna posizione attualmente
Profilo
Bruce W.
Tomlinson served as the Chief Accounting Officer, VP & Controller at InterMune, Inc. from 2009 to 2012.
He also briefly served as the Chief Financial Officer & Vice President at PDL BioPharma, Inc. in 2012.
Tomlinson received his undergraduate degree from the University of California, Los Angeles.
Precedenti posizioni note di Bruce W. Tomlinson
Società | Posizione | Fine |
---|---|---|
PDL BIOPHARMA, INC. | Direttore Finanziario/CFO | 30/11/2012 |
INTERMUNE INC | Comptroller/Controller/Auditor | 08/06/2012 |
Formazione di Bruce W. Tomlinson
University of California, Los Angeles | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
- Borsa valori
- Insiders
- Bruce W. Tomlinson